Gritstone Bio Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase II/III Study of Its Personalized Cancer Vaccine, GRANITE, in Front-Line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

The randomized, controlled, open-label study is designed to quantify the clinical benefit of maintenance therapy with GRANITE in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone.
[Gritstone bio, Inc.]
Press Release